BioLineRx Management
Management criteria checks 2/4
BioLineRx's CEO is Phil Serlin, appointed in Oct 2016, has a tenure of 8.08 years. total yearly compensation is $952.00K, comprised of 29.4% salary and 70.6% bonuses, including company stock and options. directly owns 0.014% of the company’s shares, worth $3.54K. The average tenure of the management team and the board of directors is 7.8 years and 2.9 years respectively.
Key information
Phil Serlin
Chief executive officer
US$952.0k
Total compensation
| CEO salary percentage | 29.4% |
| CEO tenure | 8.1yrs |
| CEO ownership | 0.01% |
| Management average tenure | 7.8yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
BioLineRx stock slips on $15M securities offering
Sep 19BioLineRx files for FDA approval of motixafortide in stem cell mobilization
Sep 12biolinerx GAAP EPS of -$0.01 beats by $0.08
Aug 16BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer
Jun 29BioLineRx: A Top Candidate For A Takeover Before 2022 Ends
Jun 30biolinerx EPS beats by $0.17
May 26BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma
May 04BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer
Dec 16biolinerx EPS beats by $0.32
Nov 23BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress
Nov 18BioLineRx launches mid-stage combo study in first-line pancreatic cancer
Oct 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$30m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$952k | US$280k | -US$61m |
| Sep 30 2023 | n/a | n/a | -US$52m |
| Jun 30 2023 | n/a | n/a | -US$43m |
| Mar 31 2023 | n/a | n/a | -US$32m |
| Dec 31 2022 | US$1m | US$297k | -US$25m |
| Sep 30 2022 | n/a | n/a | -US$24m |
| Jun 30 2022 | n/a | n/a | -US$22m |
| Mar 31 2022 | n/a | n/a | -US$22m |
| Dec 31 2021 | US$903k | US$290k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$34m |
| Dec 31 2020 | US$958k | US$250k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$27m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$678k | US$256k | -US$25m |
| Sep 30 2019 | n/a | n/a | -US$21m |
| Jun 30 2019 | n/a | n/a | -US$24m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$846k | US$254k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$25m |
| Jun 30 2018 | n/a | n/a | -US$26m |
| Mar 31 2018 | n/a | n/a | -US$26m |
| Dec 31 2017 | US$612k | US$240k | -US$24m |
Compensation vs Market: Phil's total compensation ($USD952.00K) is above average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: Phil's compensation has been consistent with company performance over the past year.
CEO
Phil Serlin (64 yo)
8.1yrs
Tenure
US$952,000
Compensation
Mr. Philip A. Serlin, also known as Phil, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLine...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 8.1yrs | US$952.00k | 0.014% $ 3.5k | |
| Chief Financial Officer | 8.1yrs | US$443.00k | 0.027% $ 6.8k | |
| Chief Development Officer | 7.8yrs | US$520.00k | 0.0055% $ 1.4k | |
| President of BioLineRx USA | 2.4yrs | US$1.01m | no data | |
| Head of Corporate Communications & Investor Relations | no data | no data | no data | |
| Head of BD & Strategic Advisor | 5.3yrs | no data | no data | |
| Treasurer & Budgetary Control Director | no data | no data | no data |
7.8yrs
Average Tenure
59yo
Average Age
Experienced Management: BLRX's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 20.8yrs | no data | 0.31% $ 76.2k | |
| Director | 10.8yrs | no data | no data | |
| Independent External Director | 14.3yrs | US$26.55k | no data | |
| Director | 21.8yrs | US$140.92k | no data | |
| Member of Immuno-Oncology Scientific Advisory Board | 2.9yrs | no data | no data | |
| Independent External Director | 2.3yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Director | 11.3yrs | no data | no data | |
| Member of Immuno-Oncology Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Immuno-Oncology Scientific Advisory Board | 2.9yrs | no data | no data | |
| Member of Immuno-Oncology Scientific Advisory Board | 2.9yrs | no data | no data | |
| Director | less than a year | no data | no data |
2.9yrs
Average Tenure
66yo
Average Age
Experienced Board: BLRX's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.